Skip to main navigation
  • •
  • Follow Us:
  • Facebook
  • Twitter
  • Linkedin
  • Grant Portal
Catalystpharma.com
  • About Catalyst
    • History
    • Management
    • Board Of Directors
    • Events and Presentations
    • Careers
    • Contact Us
  • Patient Focus
    • Patient Stories
      • LEMS Stories
    • Disease Information
      • LEMS
      • MuSK-MG
      • SMA
    • Patient Resources
      • Organizations
      • Event Calendar
      • Patient Engagement
  • Research & Pipeline
    • Roadmap To Success (Strategy)
    • Pipeline (clinical)
      • LEMS Clinical
    • Product
    • Business Development
    • Healthcare Professional Outreach
  • Clinical Trials
  • Responsibility
    • Corporate Giving
    • Investigator Sponsored Research
    • ESG SASB DISCLOSURE
  • Investors
    • Press Releases
    • Events & Presentations
    • SEC Filings
    • Corporate Governance
      • Documents & Charters
      • Board of Directors
      • Management
      • Committee Composition
      • Contact the Board
    • Stock Information
      • Stock Information
      • Historic Stock Lookup
    • Annual Report and Proxy
    • Analyst Coverage
    • Email Alerts
Select Page

Price to Cash Flow (FY)

  • Press Releases
  • Events & Presentations
  • SEC Filings
  • Corporate Governance
  • Stock Information
  • Annual Report and Proxy
  • Analyst Coverage
  • Email Alerts

Price to Cash Flow (FY)

This is the current Price divided by Cash Flow Per Share for the most recent fiscal year. Cash Flow is defined as Income After Taxes minus Preferred Dividends and General Partner Distributions plus Depreciation, Depletion and Amortization.
  • Email Alerts
  • RSS
  • Print page
  • Search
Catalyst Pharmaceuticals logo
  • ABOUT CATALYST
  • PATIENT FOCUS
  • RESPONSIBILITY
  • RESEARCH & PIPELINE
  • EVENTS & PRESENTATIONS
  • CAREERS
  • CONTACT US
  • CLINICAL TRIALS
CONTACT
(305) 420-3200
Email Us
Investors
 

FOLLOW US:

facebook twitter linkedin
© 2020 Catalyst Pharmaceuticals, Inc. All Rights Reserved. 19CRP0211(3) November 2019 | Privacy Policy | Accessibility Statement